PATENT CLAIM ANALYSIS

Application Number: 15923277
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["514", "046000"]

Abstract:
Provided herein are uses of pharmaceutically effective amounts of an inhibitor of an arginine methyltransferase alone or in combination with one or more bryostatins to promote regenerative synaptogenesis. Also provided are methods for promoting regenerative synaptogenesis in a patient by administering a pharmaceutically effective amount of an inhibitor of an arginine methyltransferase alone or in combination with a PKC activator to the patient. Likewise, methods are also provided are methods for promoting dendritic maturation in a patient by administering a pharmaceutically effective amount of an inhibitor of an arginine methyltransferase alone or in combination with a PKC activator to the patient, wherein the administration promotes synaptic formation in the hippocampus.

Claim (Index 55):
The method of  claim 54 , wherein the arginine methyltransferase is coactivator-associated arginine methyltransferase 1 (CARM1).

Metadata:
- Claim Count in Document: 14.0
- Percentile: 90.0
- Lexical Diversity: 2.34694
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14357654', '13817040', '13768497', '15580419', '14038973']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7511308336402469
- 35 USC 102 Novelty (BERT): 0.5270280850365021
- Combined Prediction Score: 0.7287205587798724
- Mean Citation Score: 279.00802000000004
- Max Citation Score: 318.03357
- Similarity Product: 193.2077307049477

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test